awmsg logo



degarelix (Firmagon®)


Reference No. 755

Publication date:
13/12/2012


Last review date:
30/08/2016

Appraisal information

degarelix (Firmagon®) 80 mg powder and solvent for solution for injection
degarelix (Firmagon®) 120 mg powder and solvent for solution for injection


Company: Ferring Pharmaceuticals (UK)
BNF category: Malignant disease and immunosupression
NMG meeting date: 09/10/2012
AWMSG meeting date: 14/11/2012
   
   
Submission Type: Resubmission
Status: Superseded
Advice No: 4112
Ministerial ratification: 11/12/2012

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE (TA404) NICE GUIDANCE ISSUED AUGUST 2016 (Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology) Degarelix (Firmagon®) is recommended as an option for use within NHS Wales for the treatment of adult male patients with advanced hormone-dependent prostate cancer. This recommendation applies only in circumstances where the approved Wales Patient Access Scheme (WPAS) is utilised or where the list/contract price is equivalent to or lower than the WPAS price.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download